It seems as though the drugs that are utilized for glioblastoma, amongst other conditions, are not going to be used at the onset. Instead, it seems as though there are many different aspects that have to be assessed before they are put to use in various therapies. Once time as passed, it is clear that researchers will be able to put them to use in the long term. With this in mind, I think that it is prudent to make note of a particular drug that has been dubbed VB-111.
An article on Pharmaceutical Business Review spoke about VB-111 and there is quite a bit to go over in this regard. Recently, the drug was responsible for VBL Therapeutics being given fast track status from the US Food and Drug Administration. What this particular drug is able to do, in theory, is extend survival rates in patients with glioblastoma. When considering the potential impact that VB-111 can have, it's no wonder as to why this particular status was given. There is more to consider, though, as organizations like Voices against Brain Cancer can tell you.
It's not like drug failed in drawing attention to itself in the past, if you would like to know. In fact, the article said that, previously, VB-111 had orphan drug status for this particular condition. It's clear that it was put to use for that purpose, seeing as how glioblastoma typically has a poor prognosis. There are no solid treatments at this time and the work that is done by researchers involves various therapies consisting of particular drugs that could prove useful for targeting the tumors as closely as possible.
This drug is given to patients through IV fusion and this is able to allow it to target the impacted areas of the body. In particular, it can bring care to the endothelial cells, as the report said that the drug can prove useful as a biological knife of sorts. There is also the point to make that only the impacted areas will be the only ones that will be targeted. What this means is that the noncancerous tissue around the brain is not going to be harmed during this particular process.
Procedures in the medical field should be effective, not leaving a trace of harm on the body in the long term. I think that this is where VB-111 could possibly come into play and I think that the findings, so far, are very strong. Its fast track status speaks volumes, especially when you consider that it promotes safety more so than anything else. Hopefully this drug is utilized on a consistent basis so that it can, in time, help those who are impacted by this condition.
An article on Pharmaceutical Business Review spoke about VB-111 and there is quite a bit to go over in this regard. Recently, the drug was responsible for VBL Therapeutics being given fast track status from the US Food and Drug Administration. What this particular drug is able to do, in theory, is extend survival rates in patients with glioblastoma. When considering the potential impact that VB-111 can have, it's no wonder as to why this particular status was given. There is more to consider, though, as organizations like Voices against Brain Cancer can tell you.
It's not like drug failed in drawing attention to itself in the past, if you would like to know. In fact, the article said that, previously, VB-111 had orphan drug status for this particular condition. It's clear that it was put to use for that purpose, seeing as how glioblastoma typically has a poor prognosis. There are no solid treatments at this time and the work that is done by researchers involves various therapies consisting of particular drugs that could prove useful for targeting the tumors as closely as possible.
This drug is given to patients through IV fusion and this is able to allow it to target the impacted areas of the body. In particular, it can bring care to the endothelial cells, as the report said that the drug can prove useful as a biological knife of sorts. There is also the point to make that only the impacted areas will be the only ones that will be targeted. What this means is that the noncancerous tissue around the brain is not going to be harmed during this particular process.
Procedures in the medical field should be effective, not leaving a trace of harm on the body in the long term. I think that this is where VB-111 could possibly come into play and I think that the findings, so far, are very strong. Its fast track status speaks volumes, especially when you consider that it promotes safety more so than anything else. Hopefully this drug is utilized on a consistent basis so that it can, in time, help those who are impacted by this condition.
About the Author:
Visit Voices Against Brain Cancer if you are seeking some additional information about brain cancer awareness.
Aucun commentaire:
Enregistrer un commentaire